All Title Author
Keywords Abstract

PLOS ONE  2013 

TGF-Beta Suppresses VEGFA-Mediated Angiogenesis in Colon Cancer Metastasis

DOI: 10.1371/journal.pone.0059918

Full-Text   Cite this paper   Add to My Lib

Abstract:

The FET cell line, derived from an early stage colon carcinoma, is non-tumorigenic in athymic nude mice. Engineered FET cells that express TGF-α (FETα) display constitutively active EGFR/ErbB signaling. These cells readily formed xenograft tumors in athymic nude mice. Importantly, FETα cells retained their response to TGF-beta-mediated growth inhibition, and, like the parental FET cells, expression of a dominant negative TGF-beta type II receptor (DNRII) in FETα cells (FETα/DNRII) abrogated responsiveness to TGF-beta-induced growth inhibition and apoptosis under stress conditions in vitro and increased metastatic potential in an orthotopic model in vivo, which indicates metastasis suppressor activity of TGF-beta signaling in this model. Cancer angiogenesis is widely regarded as a key attribute for tumor formation and progression. Here we show that TGF-beta signaling inhibits expression of vascular endothelial growth factor A (VEGFA) and that loss of autocrine TGF-beta in FETα/DNRII cells resulted in increased expression of VEGFA. Regulation of VEGFA expression by TGF-beta is not at the transcriptional level but at the post-transcriptional level. Our results indicate that TGF-beta decreases VEGFA protein stability through ubiquitination and degradation in a PKA- and Smad3-dependent and Smad2-independent pathway. Immunohistochemical (IHC) analyses of orthotopic tumors showed significantly reduced TGF-beta signaling, increased CD31 and VEGFA staining in tumors of FETα/DNRII cells as compared to those of vector control cells. These results indicate that inhibition of TGF-beta signaling increases VEGFA expression and angiogenesis, which could potentially contribute to enhanced metastasis of those cells in vivo. IHC studies performed on human colon adenocarcinoma specimens showed that TGF-beta signaling is inversely correlated with VEGFA expression, indicating that TGF-beta-mediated suppression of VEGFA expression exists in colon cancer patients.

References

[1]  Valdes F, Alvarez AM, Locascio A, Vega S, Herrera B, et al. (2002) The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes. Mol Cancer Res 1: 68–78.
[2]  Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, et al. (2002) Ras and TGF-[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 156: 299–313.
[3]  Oft M, Heider KH, Beug H (1998) TGF-beta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8: 1243–1252.
[4]  Wang J, Han W, Zborowska E, Liang J, Wang X, et al. (1996) Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells. J Biol Chem 271: 17366–17371.
[5]  Ye SC, Foster JM, Li W, Liang J, Zborowska E, et al. (1999) Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells. Cancer Res 59: 4725–4731.
[6]  Wang J, Sun L, Myeroff L, Wang X, Gentry LE, et al. (1995) Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 270: 22044–22049.
[7]  Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, et al. (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268: 1336–1338.
[8]  Sun L, Wu G, Willson JK, Zborowska E, Yang J, et al. (1994) Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 269: 26449–26455.
[9]  Wang J, Sergina N, Ko TC, Gong J, Brattain MG (2004) Autocrine and exogenous transforming growth factor beta control cell cycle inhibition through pathways with different sensitivity. J Biol Chem 279: 40237–40244.
[10]  Wu SP, Theodorescu D, Kerbel RS, Willson JK, Mulder KM, et al. (1992) TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol 116: 187–196.
[11]  Wu SP, Sun LZ, Willson JK, Humphrey L, Kerbel R, et al. (1993) Repression of autocrine transforming growth factor beta 1 and beta 2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties. Cell Growth Differ 4: 115–123.
[12]  Simms N, Rajput A, Sharratt EA, Ongchin M, Teggart CA, et al. (2012) Transforming growth factor-β suppresses metastasis in a subset of human colon carcinoma cells. BMC Cancer 12: 221.
[13]  Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18: 4–25.
[14]  Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69 Suppl 34–10.
[15]  Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401–410.
[16]  Akiri G, Nahari D, Finkelstein Y, Le SY, Elroy-Stein O, et al. (1998) Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 17: 227–236.
[17]  Bornes S, Prado-Lourenco L, Bastide A, Zanibellato C, Iacovoni JS, et al. (2007) Translational induction of VEGF internal ribosome entry site elements during the early response to ischemic stress. Circ Res 100: 305–308.
[18]  Fatyol K, Szalay AA (2001) The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits HIF-1-mediated transcription. J Biol Chem 276: 28421–28429.
[19]  Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604–4613.
[20]  Qian D, Lin HY, Wang HM, Zhang X, Liu DL, et al. (2004) Involvement of ERK1/2 pathway in TGF-beta1-induced VEGF secretion in normal human cytotrophoblast cells. Mol Reprod Dev 68: 198–204.
[21]  Riedel K, Riedel F, Goessler UR, Germann G, Sauerbier M (2007) TGF-beta antisense therapy increases angiogenic potential in human keratinocytes in vitro. Arch Med Res 38: 45–51.
[22]  Rajput A, Koterba AP, Kreisberg JI, Foster JM, Willson JK, et al. (2007) A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. Cancer Res 67: 665–673.
[23]  Yu L, Hebert MC, Zhang YE (2002) TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J 21: 3749–3759.
[24]  Zhu B, Zhai J, Zhu H, Kyprianou N (2010) Prohibitin regulates TGF-beta induced apoptosis as a downstream effector of Smad-dependent and -independent signaling. Prostate 70: 17–26.
[25]  Chowdhury S, Howell GM, Rajput A, Teggart CA, Brattain LE, et al. (2011) Identification of a novel TGF-beta/PKA signaling transduceome in mediating control of cell survival and metastasis in colon cancer. PLoS ONE 6: e19335.
[26]  Fleming N, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, et al.. (2012) SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res.
[27]  Wang J, Yang L, Yang J, Kuropatwinski K, Wang W, et al. (2008) ransforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells. Cancer Res 68: 3152–3160.
[28]  Hajra KM, Liu JR (2004) Apoptosome dysfunction in human cancer. Apoptosis 9: 691–704.
[29]  Losi L, Bouzourene H, Benhattar J (2007) Loss of Smad4 expression predicts liver metastasis in human colorectal cancer. Oncol Rep 17: 1095–1099.
[30]  Miyaki M, Iijima T, Konishi M, Sakai K, Ishii A, et al. (1999) Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 18: 3098–3103.
[31]  Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, et al. (2010) Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology 138: 969–980.
[32]  Papageorgis P, Cheng K, Ozturk S, Gong Y, Lambert AW, et al. (2011) Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res 71: 998–1008.
[33]  Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjanen S, et al. (2008) VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res 28: 3865–3870.
[34]  Bertolini F, Malavasi N, Scarabelli L, Fiocchi F, Bagni B, et al. (2011) FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer 104: 1079–1084.
[35]  Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, et al. (2010) Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol 17: 2059–2065.
[36]  Tejpar S, Prenen H, Mazzone M (2012) Overcoming Resistance to Antiangiogenic Therapies. Oncologist 17: 1039–1050.

Full-Text

comments powered by Disqus